Press Releases Merck & Co., Inc. London S.E.

Equities

0QAH

US58933Y1055

Real-time Estimate Tradegate Other stock markets 04:00:00 2024-07-03 EDT			5-day change	1st Jan Change
119.6 ^EUR	0.00%		+2.60%	0.00%

07-01	Merck, Orion Convert Ongoing Collaboration Into Exclusive Global License for Opevesostat	MT
07-01	Merck: license agreement with Orion Corp. for opevesostat	CF

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Innoviva Specialty Therapeutics, Inc. Appoints Patricia Drake as Chief Commercial Officer	07-02	AQ
Merck and Orion Announce Mutual Exercise of Option Providing Merck Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Prostate Cancer	07-01	BU
Merck to Hold Second-Quarter 2024 Sales and Earnings Conference Call July 30	07-01	BU
CDC'S ACIP Unanimously Recommends Merck's CAPVAXIVE for Pneumococcal Vaccination in Appropriate Adults	06-28	AQ
EISAI - NEW EFFICACY DATA FOR NON-CLEAR CELL RENAL CELL CARCINOMA FROM KEYNOTE-B61 ADDED TO LENVIMA US LABEL SUPPORTING KEYTRUDA + LENVIMA INDICATION FOR THE FIRST-LINE TREATMENT OF ADULT PATIENTS WITH ADVANCED RCC	06-28	AQ
Immutep Reports Positive Topline Results from TACTI-003 Phase IIb Trial in First Line Head and Neck Cancer	06-28	AQ
Merck Receives Positive EU CHMP Opinion for WINREVAIR™ (sotatercept) in Pulmonary Arterial Hypertension (PAH)	06-28	BU
CDC’S ACIP Unanimously Recommends Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Appropriate Adults	06-27	BU
Merck : CDC’s ACIP Unanimously Votes to Add Merck and Sanofi’s Pediatric Hexavalent Combination Vaccine to its Preferential Recommendation to Help Prevent Invasive Hib Disease in American Indian and Alaska Native Infants - Merck.com	06-27	PU
Merck - Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer	06-27	AQ
Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer	06-26	BU
USDA Approves Merck Animal Health's NOBIVAC NXT Canine Flu H3N2, The First and Only RNA-Particle Technology Vaccine for Canine Influenza	06-26	AQ
USDA Approves Merck Animal Health’s NOBIVAC® NXT Canine Flu H3N2 – The First and Only RNA-Particle Technology Vaccine for Canine Influenza	06-25	BU
Merck - U.S. FDA Approves CAPVAXIVE for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults	06-18	AQ
FDA Approves Merck s KEYTRUDA plus Carboplatin and Paclitaxel as Treatment for Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma	06-18	AQ
U.S. FDA Approves CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults	06-17	BU
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Carboplatin and Paclitaxel as Treatment for Adult Patients With Primary Advanced or Recurrent Endometrial Carcinoma	06-17	BU
Merck to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference	06-05	BU
Silo Pharma's (NASDAQ: SILO) Promising Developments and Key Insights for Traders and Investors	06-04	AQ
Anaveon announces IND approval of ANV600-001 Phase I/II clinical study	05-30	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Merck & Co., Inc. London S.E.

Equities

0QAH

US58933Y1055

Press Releases

Filters